Assignee
CRYSTALGENOMICS INC
KR·7 granted patents·11 pending applications·38 citations·filing 2006–2023
Top patents by PatentIndex Score
18 records- 0191US9758508B22,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including sameCRYSTALGENOMICS INC·Filed 2013·Granted Sep 12, 2017·33 cites·15 claims
- 0280US7973060B2Fab I inhibitor and process for preparing sameCRYSTALGENOMICS INC·Filed 2006·Granted Jul 5, 2011·4 cites·18 claims
- 0379US11655207B2Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing sameCRYSTALGENOMICS INC·Filed 2018·Granted May 23, 2023·1 cites·14 claims
- 0471US2022380346A12,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including sameCRYSTALGENOMICS INC·Filed 2022·Application pending·0 cites
- 0567US2023157991A1Pharmaceutical composition for treating acute and chronic pain, containing polmacoxib and tramadolCRYSTALGENOMICS INC·Filed 2023·Application pending·0 cites
- 0666US2023293476A1Pharmaceutical composition, comprising polmacoxib and pregabalin, for treatment of painCRYSTALGENOMICS INC·Filed 2023·Application pending·0 cites
- 0765US11602517B2Pharmaceutical composition, comprising polmacoxib and pregabalin, for treatment of painCRYSTALGENOMICS INC·Filed 2019·Granted Mar 14, 2023·0 cites·19 claims
- 0864US11230539B22,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including sameCRYSTALGENOMICS INC·Filed 2020·Granted Jan 25, 2022·0 cites·22 claims
- 0962US10604508B22,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including sameCRYSTALGENOMICS INC·Filed 2017·Granted Mar 31, 2020·0 cites·22 claims
- 1055US2020276152A1Pharmaceutical composition for treating acute and chronic pain, containing polmacoxib and tramadolCRYSTALGENOMICS INC·Filed 2018·Application pending·0 cites
- 1152US2022287993A1Pharmaceutical composition comprising hdac inhibitor and anti-pd1 antibody or anti pd-l1 antibodyCRYSTALGENOMICS INC·Filed 2020·Application pending·0 cites
- 1249US10413520B2Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stabilityCRYSTALGENOMICS INC·Filed 2017·Granted Sep 17, 2019·0 cites·9 claims
- 1349US2021346321A1Pharmaceutical composition containing alkyl carbamoyl naphthalenyloxy octenoyl hydroxyamide phosphate, tartrate or combination thereof, and preparation method thereforCRYSTALGENOMICS INC·Filed 2019·Application pending·0 cites
- 1449US2021015772A1Pharmaceutical composition for prevention or treatment of fibrosisCRYSTALGENOMICS INC·Filed 2019·Application pending·0 cites
- 1547US2022016098A1Orally administered pharmaceutical composition comprising fab i inhibitors and method for preparing sameCRYSTALGENOMICS INC·Filed 2019·Application pending·0 cites
- 1646US2022031607A1Injection composition containing fab i inhibitor, and preparation method thereforCRYSTALGENOMICS INC·Filed 2020·Application pending·0 cites
- 1742US2011028507A1Pyridine derivatives and methods of use thereofCRYSTALGENOMICS INC·Filed 2008·Application pending·0 cites
- 1826US2017000759A1Pharmaceutical Composition Including 5--2,2-Dimethyl-4-(3-Fluorophenyl)-3(2H)-Furanone And Capsule Formulation Including The Pharmaceutical CompositionCRYSTALGENOMICS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CRYSTALGENOMICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →